NYSE: CICigna Group Stock
$320.94+12.08 (+3.91%)
Updated May 16, 2025
CI Price
$320.94
Fair Value Price
N/A
Market Cap
$85.74B
52 Week Low
$262.03
52 Week High
$370.83
P/E
17.67x
P/B
2.13x
P/S
0.35x
PEG
0.67x
Dividend Yield
1.78%
Revenue
$255.37B
Earnings
$5.03B
Gross Margin
10.3%
Operating Margin
3.11%
Profit Margin
2%
Debt to Equity
2.74
Operating Cash Flow
$7B
Beta
0.5
Next Earnings
N/A
Ex-Dividend
Jun 3, 2025
Next Dividend
Jun 18, 2025
CI Overview
Cigna Corporation is a managed healthcare and insurance company. It provides medical, dental, disability, life and accident insurance, primarily through employer-sponsored plans. Its Evernorth segment provides pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. Cigna was founded in 1982 and is headquartered in Bloomfield, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CI's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
A
CI
Ranked#1 of 10
Ranked#1 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $62.53 | B | |
| $61.78 | B | |
| $403.29 | B |
Be the first to know about important CI news, forecast changes, insider trades & much more!
CI News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CI scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CI ($320.94) is trading above its intrinsic value of $262.97, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CI is good value based on its earnings relative to its share price (17.67x), compared to the US market average (25.95x)
P/E vs Market Valuation
CI is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CI due diligence checks available for Premium users.
Valuation
CI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.67x
Industry
13.66x
Market
25.95x
CI is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.13x
Industry
1.99x
CI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CI price to earnings growth (PEG)
For valuing profitable companies with growth potential
CI is good value based... subscribe to Premium to read more.
PEG Value Valuation
CI's financial health
Profit margin
Revenue
$65.5B
Net Income
$1.3B
Profit Margin
2%
CI's Earnings (EBIT) of $7.95B... subscribe to Premium to read more.
Interest Coverage Financials
CI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$150.7B
Liabilities
$110.2B
Debt to equity
2.74
CI's short-term liabilities ($55.75B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CI's long-term liabilities ($54.50B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.9B
Investing
$1.2B
Financing
-$3.7B
CI's operating cash flow ($7.44B)... subscribe to Premium to read more.
Debt Coverage Financials
CI vs Healthcare Plan Stocks
Cigna Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.